• Channels
    • All News
    • Premium Stories
    • R&D
    • Pharma
    • Venture
    • People
    • Startups
    • Regulatory
    • Deals
    • IPOs
    • China
    • Cell/Gene Tx
    • Bioregnum
    • Peer Review
    • Discovery
    • Outsourcing
    • AI
    • Special
  • Events
  • Biopharma Jobs
  • More
    • Webinars
    • Sponsored Posts
    • Biotech Voices
    • Advertise
    • Privacy Policy
    • About Us
    • Help
  • SUBSCRIBE

As­traZeneca chal­lenges Roche on front­line SCLC af­ter seiz­ing an in­ter­im win — and Mer­ck may not be far be­hind

5 months ago
R&D

Top an­a­lyst finds a sil­ver lin­ing in Ab­b­Vie’s $63B Al­ler­gan buy­out — but there’s a catch

5 months ago
Deals

Af­ter rais­ing $158M, this up­start's founders have star back­ers and plans to break new ground in gene ther­a­py

5 months ago
Cell/Gene Tx
Startups

Ab­b­Vie's $63B buy­out spot­lights the re­turn of ma­jor M&A deals — de­spite the back­lash

5 months ago
Deals

Ab­b­Vie seals $63B deal to buy a trou­bled Al­ler­gan — spelling out $1B in R&D cuts

5 months ago
Deals

In sur­prise switch, Bris­tol-My­ers is sell­ing off block­buster Ote­zla, promis­ing to com­plete Cel­gene ac­qui­si­tion — just lat­er

5 months ago
Deals

Why would the FDA ap­prove an­oth­er con­tro­ver­sial drug to spur a woman’s li­bido with these da­ta? And why no ex­pert pan­el re­view?

5 months ago
Bioregnum
Pharma

Which top 10 big phar­mas have the most to gain — or lose — over the next 5 years?

5 months ago
Pharma

HIV, pneu­mo­coc­cal — and what? Mer­ck­'s un­ex­pect­ed pipeline high­light ex­cites a lit­tle biotech

5 months ago
R&D

Who’s next in line to suc­ceed Ken Fra­zier as CEO of the Keytru­da-blessed Mer­ck?

5 months ago
People

Sanofi's John Reed con­tin­ues to re­or­ga­nize R&D, cut­ting 466 jobs while boost­ing can­cer, gene ther­a­py re­search

5 months ago
R&D

A new num­ber 1 drug? Keytru­da tapped to top the 10 biggest block­busters on the world stage by 2024

5 months ago
Pharma

'It's a growth play': Catal­ent ac­quires Bris­tol-My­er­s' Eu­ro­pean launch pad, ex­pand­ing glob­al CD­MO ops

5 months ago
Deals
Outsourcing

Af­ter watch­ing its share price soar on a Bloomberg re­port and heat­ed ru­mors, Bio­haven stock takes a bil­lion-dol­lar bath

5 months ago
Bioregnum

The top 10 block­buster drugs in the late-stage pipeline — Eval­u­ate adds 6 new ther­a­pies to heavy-hit­ter list

5 months ago
R&D

As Bris­tol-My­ers/Cel­gene tie up loose ends, BeiGene pock­ets $150M from PD-1 breakup

5 months ago
China
Deals

Pfiz­er CEO Al­bert Bourla is back in the M&A game, but why is he pay­ing $11.4B for Ar­ray?

5 months ago
Deals

Glob­al Blood Ther­a­peu­tics poised to sub­mit ap­pli­ca­tion for ac­cel­er­at­ed ap­proval, with new piv­otal da­ta on its sick­le cell dis­ease drug

5 months ago
R&D

Gene ther­a­pies seize the top of the list of the most ex­pen­sive drugs on the plan­et — and that trend has just be­gun

5 months ago
Cell/Gene Tx
Pharma

As an­oth­er an­tibi­otics biotech sinks in­to a cri­sis, warn­ings of a sec­tor ‘col­lapse’

5 months ago
R&D

Bain’s biotech team has cre­at­ed a $1B-plus fund — with an eye to more Big Phar­ma spin­outs

6 months ago
Venture

Search­ing for the next block­buster to fol­low Darza­lex, J&J finds a $150M an­ti-CD38 drug from part­ner Gen­mab

6 months ago
R&D

Mer­ck makes a $773M bet on TGFβ, ac­quir­ing a three-year-old biotech

6 months ago
Deals

As in­vestor con­fi­dence crum­bles fol­low­ing fund sus­pen­sion, Neil Wood­ford faces back­lash on fees

6 months ago
Pharma
First page Previous page 13141516171819 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Premium Stories
  • Don't Miss

Channels

  • R&D
  • Pharma
  • Venture
  • People
  • Startups
  • Regulatory
  • Deals
  • IPOs
  • China
  • Cell/Gene Tx
  • Bioregnum
  • Peer Review
  • Discovery
  • Outsourcing
  • AI
  • Special

More

  • Events
  • Webinars
  • Sponsored Posts
  • Biotech Voices
  • Advertise
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© 2019 — Endpoints Company

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
Endpoints News

Sign in to your account

e-mail

password

Endpoints News

request magic link

If you're already an Endpoints subscriber, enter your email below for a magic link that lets you sign in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.

email

Endpoints News

reset password

We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.

email

Endpoints News

About You

Subscriptions

ENDPOINTS by John Carroll & team — all the news at 11:30a ET

EARLY EDITIONby Arsalan Arif — skimmable links and news at 7:15a ET